Müge kopuz alvarez noval

Müge kopuz alvarez noval


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2024 in Prostaglandins & Other Lipid Mediators
Verified
Journal Article
Closed access
AKAçelya GÜL KOYUNCU
Açelya GÜL KOYUNCU
ACAlev Cumbul
Alev Cumbul
MNMüge kopuz alvarez noval
Müge kopuz alvarez noval
Elvan Yılmaz AkyüzElvan Yılmaz Akyüz
Elvan Yılmaz Akyüz

Verified
Journal Article
Open access
PDF file
LŞLuay 1 Şerifoğlu
Luay 1 Şerifoğlu
MNMüge kopuz alvarez noval
Müge kopuz alvarez noval
SBSELVİ DUMAN BAKIREZER
SELVİ DUMAN BAKIREZER
SYSeda Güleç Yılmaz
Seda Güleç Yılmaz
EVEyüp Varol
Eyüp Varol
SÖSelçuk Özdoğan
Selçuk Özdoğan
Background/Objectives: The aim of the study is to investigate the role of microRNA-17 (miRNA-17), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) in the pathogenesis of lumbar degenerative disc disease (LDDD). The goal is to explore how miRNA-17 regulates inflammation and apoptosis within the intervertebral discs, with a particular focus on its involvement in inflammatory pathways via NF-κB signaling. This research seeks to uncover the molecular mechanisms that contribute to LDDD and its associated chronic lower back pain and disability. Methods: A case–control study was conducted, involving 110 patients diagnosed with LDDD and 17 healthy control individuals. Serum levels of miRNA-17, TNF-α, and IL-6 were measured using quantitative real-time PCR and enzyme-linked immunosorbent assays (ELISAs). The patients were further categorized based on the severity of their condition using the Oswestry Disability Index (ODI), which classified them into five subgroups. The correlation between miRNA-17 expression, pro-inflammatory cytokines, and disease severity was analyzed statistically. Results: The results demonstrated a significant downregulation of microRNA-17 in patients with LDDD compared to healthy controls. Inflammatory markers TNF-α and IL-6 were found to be significantly elevated in the patient group. A peak in inflammation and miRNA-17 expression was observed in patients with moderate to severe disability (ODI Grade 3), while inflammation levels decreased in more advanced stages of the disease (ODI Grades 4 and 5), suggesting a possible shift in disease dynamics. Conclusions: This study demonstrates that miRNA-17 plays a regulatory role in inflammation during the progression of LDDD, particularly through the modulation of TNF-α and IL-6 levels. The findings indicate that inflammation is most pronounced in the mid-stages of LDDD, while the later stages are characterized by structural damage rather than ongoing inflammation. These insights could help guide future therapeutic strategies aimed at targeting the molecular mechanisms underlying LDDD, potentially improving patient outcomes.

15 January 2026 in Neurosurgical Review
Verified
Journal Article
Open access
PDF file
CYC. Kaan Yaltırık
C. Kaan Yaltırık
GÖGonca Gül Öndüç
Gonca Gül Öndüç
MNMüge kopuz alvarez noval
Müge kopuz alvarez noval
MEMustafa Umut Etli
Mustafa Umut Etli
CSCaner Sarıkaya
Caner Sarıkaya
SÖSelçuk Özdoğan
Selçuk Özdoğan
Lumbar degenerative disc disease (LDDD) is characterized by persistent inflammation and extracellular matrix degradation. Emerging as main controllers in its pathogenesis are microRNAs (miRNAs) and proinflammatory cytokines. Through the JAK/STAT signalling pathway, HSA-miR-186-5p has been linked to modulating cytokine expression, including interleukin-2 (IL-2). The aim is to find the expression levels of IL-2 and HSA-miR-186-5p in LDDDpatients and investigate their possible correlation with disease degree. 110 LDDD patients and 17 healthy controls wereincluded. ELISA measured serum IL-2 concentrations, and RT-qPCRestimated miR-186-5p levels. The Oswestry Disability Index (ODI) guidedpatients into five subgroups (G1–G5). One-way ANOVA and correlationanalysis were applied in statistical comparisons. LDDD patients had notably higher IL-2 levels than controls ( p <0.001). According to the subgroup analysis, the IL-2 concentration peaked inG2 and G3 and gradually dropped toward G5. By contrast, miR-186-5pexpression was noticeably lowered in the LDDD group ( p < 0.001), with G1and G5 having the lowest levels found. Across groups, an inverse trend in IL-2 and miR-186-5p expression was noted. Results imply a dysregulated interaction between HSA-miR-186-5p and IL-2 in LDDD. Particularly in early and moderate stages ofdisease, miR-186-5p downregulation could help to explain increased IL-2-mediated inflammation. These biomarkers could provide information ondisease activity and present targets for new treatments.